At DKI, we’ve been making an effort to be more transparent in how we make investment decisions and to provide more educational content. There are several interesting lessons which can be extracted from the recent scPharma takeover announcement. Before we dive in, I want to be clear that while a likely acquisition was a key ... Read more The post scPharmaceuticals ($SCPH) – Educational Lessons from a Deal appeared first on Deep Knowledge Investing.| Deep Knowledge Investing
MannKind is acquiring DKI portfolio position scPharmaceuticals ($SCPH) for $5.35/share in cash plus a contingent value right (CVR) worth up to $1.00/share. The full value represents a 31% premium to Friday’s closing price. MannKind has the necessary financing from Blackstone. This is the second DKI healthcare device portfolio company acquired in the past two ... Read more The post scPharmaceuticals ($SCPH) – Being Acquired by MannKind for a Large Premium appeared first on Deep Knowledg...| Deep Knowledge Investing
MannKind is acquiring DKI portfolio position scPharmaceuticals ($SCPH) for $5.35/share in cash plus a contingent value right (CVR) worth up to $1.00/share. The full value represents a 31% premium to Friday’s closing price. MannKind has the necessary financing from Blackstone. I’m listening to the conference call right now and will update you later today when ... Read more The post scPharmaceuticals ($SCPH) Being Acquired – Large Premium appeared first on Deep Knowledge Investing.| Deep Knowledge Investing